GoAI
Get started
Veradermics, Incorporated logo

Veradermics, Incorporated

MANE

NYSEHealthcareBiotechnology

Open in GoAI

Latest quote

$102.82

Market data unavailable

MANE company overview

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

40

Expensive

Momentum

70

Gaining

Sentiment

58

Mixed

Risk resilience

59

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Volume
337.59K
Market cap
4.3B USD

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.3B USD
P/E (TTM)
-48.05×
P/B (TTM)
5.11×
P/S (TTM)
0×
EV / EBITDA
-18.61×
Earnings yield
-5.29%
Free cash flow yield
-5.41%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
57.84%
Return on assets
-45.86%
Return on invested capital
-50.43%

Financial health

Debt / equity
0×
Current ratio
16.66×

Financial statements

Income trends

Operating income

−72.35M USD-170.17%

Net income

−70M USD-164.25%
Income trends across reported periods−10.9M USD−33.25M USD−55.59M USD−77.93M USDOperating income, FY2023: −17.32M USDOperating income, FY2024: −26.78M USDOperating income, FY2025: −72.35M USDNet income, FY2023: −16.49M USDNet income, FY2024: −26.49M USDNet income, FY2025: −70M USDFY2023FY2024FY2025
Operating income FY2023 −17.32M USD. Operating income FY2024 −26.78M USD. Operating income FY2025 −72.35M USD. Net income FY2023 −16.49M USD. Net income FY2024 −26.49M USD. Net income FY2025 −70M USD.
Metric (USD)FY2025FY2024FY2023
Research and development62.07M USD23.28M USD14.97M USD
Selling, general, and administrative10.28M USD3.5M USD2.35M USD
Operating expenses72.35M USD26.78M USD17.32M USD
Interest income1.56M USD481K USD870K USD
Interest expense—585K USD36K USD
Operating income−72.35M USD−26.78M USD−17.32M USD
Net income−70M USD−26.49M USD−16.49M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
67%
2 beats, 1 miss, 0 met estimates
Average EPS surprise
-38.32%
3 comparable reports
Latest EPS result
-0.58
Estimate -0.65 · Beat by 10.43%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.48-0.95-1.43-1.91Q4 '25No estimateQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q4 2025, reported Dec 3, 2025: actual -1.63, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 25, 2026: actual -1.63, estimate -1.81, surprise +10.31%, Beat. Q2 2026, reported May 12, 2026: actual -1.32, estimate -0.56, surprise -135.71%, Miss. Q3 2026, reported Aug 11, 2026: actual -0.58, estimate -0.648, surprise +10.43%, Beat. Q4 2026, reported Nov 10, 2026: actual —, estimate -0.59, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy4100%
Hold00%
Sell00%
Strong sell00%

MANE news

defenseworld.net

Insider Selling: Veradermics (NYSE:MANE) Director Sells $10,712,000.00 in Stock

Veradermics, Incorporated (NYSE: MANE - Get Free Report) Director John Childs sold 100,000 shares of Veradermics stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $107.12, for a…

Read source
gurufocus.com

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern

Read source
businesswire.com

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported…

Read source
seekingalpha.com

Veradermics: VDPHL01 Looks Promising Enough On Paper

MANE's main drug candidate is VDPHL01. This asset already has encouraging male and female data for hair loss. However, VDPHL01 still needs pivotal data to make it ready for a potential FDA submission. If approved,…

Read source
businesswire.com

Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today…

Read source
defenseworld.net

Veradermics (NYSE:MANE) Shares Gap Up After Analyst Upgrade

Veradermics, Incorporated (NYSE: MANE - Get Free Report)'s stock price gapped up before the market opened on Wednesday after Citigroup raised their price target on the stock from $135.00 to $160.00. The stock had…

Read source

MANE peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

+0.83%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

+1.07%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

+1.21%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

+2.39%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

+1.37%

Novartis AG logo

NVS

Novartis AG

$158.86

+1.68%

Continue in GoAI

Research MANE

research.disclaimer